# Pizarra — PT-pseudo_3646e0a2ae13 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3646e0a2ae13
Task: 1

Encounter: Urology - outpatient on 20 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.5 ng/mL
  - mpMRI — PI-RADS score: NA (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.095 ng/mL²
  - PSA velocity: 0.6 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 47.29 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.5290899 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Chronic kidney disease
  - Problem list / PMHx: Type 2 diabetes, Chronic kidney disease
  - Current medication: metformin, empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 4.5 ng/mL. PI-RADS NA. PSAD 0.10. Prostate volume 47 mL. csPCa 0.53.

Vitals: weight 88 kg, height 194 cm, BMI 23.4, BP 126/80 mmHg, HR 68 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2012).

Chief complaint: Evaluation of a steadily increasing prostate-specific antigen level alongside newly acquired multiparametric imaging data.

History: At sixty-seven, this patient is a small business owner (cafe) and maintains a vigorous fitness regimen of three five-kilometre runs each week. Former tobacco use totals 31 pack-years, though cessation occurred in 2012. His medical background includes Type 2 diabetes and Chronic kidney disease, currently managed with metformin and empagliflozin. A recent vascular consultation addressed asymptomatic varicose veins, and a laparoscopic cholecystectomy was performed in 2008. He lives in a retirement community (independent unit) following the loss of his wife two years prior. Only mild lower urinary tract symptoms are reported, yielding an IPSS score of 5. He denies prior prostate interventions or catheterization, and his biopsy bucket records as None, yet voiced considerable hesitation regarding any invasive diagnostic procedures during this consultation. Occasional seasonal allergies round out his clinical profile.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland measures symmetrically without discrete nodules. Systemic vitals remain stable, registering 126/80 mmHg with a regular pulse at 68 beats per minute. Palpation of the abdomen reveals no tenderness or masses.

Patient info: small business owner (cafe); Widowed; Lives in retirement community (independent unit).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.79 +/- 0.17   (95% CI 0.36-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.13  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.7 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  bx_ord=0.0, psa=4.5, age=67.0, psad=0.095, dre_ord=0.0, vol=47.29, n_pmhx=2.0
  missing / not evaluable: pirads

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: DEFER BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PSA 4.5, PI-RADS NA, PSA density 0.095, age 67, DRE Normal, Volume 47.29 mL, csPCa probability 0.529) and failed to incorporate the crucial missing information: the actual mpMRI report, the PSA trajectory (velocity 0.6 ng/mL/yr), and the specific PI-RADS score (NA).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability (0.79), but this ignores the EXPERT-PROTOCOL's criterion that biopsy should be deferred when PI-RADS is 1-2. Furthermore, the prior cannot reconcile the high csPCa probability (0.53) with the DRE finding of 'Normal' and the 'NA' PI-RADS score, which are contradictory signals that require imaging context. The prior's wide uncertainty interval suggests it cannot handle the ambiguity introduced by the missing imaging data.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology / mpMRI report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - to check for any prior discussions regarding biopsy hesitation
laboratory panel - to confirm the PSA density value and check for other relevant markers
family-history anamnesis - to assess for genetic risk factors

GUIDELINE ANCHOR
The guideline suggests deferring biopsy when the mpMRI shows a PI-RADS 1-2 lesion, and the track record shows that PI-RADS 3 lesions are associated with a 20% detection rate of ISUP $\ge$ 2 cancer.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI Report: Subject: Prostate mpMRI | Amsterdam UMC VUmc. Findings indicate no PI-RADS 3+ lesion identified. The gland measures 47.29 mL overall. No suspicious focal lesion is identified. PI-RADS NA.
get_psa_trend
PSA Trend: Shows a rising trajectory from 1.0 ng/mL (Aug 2022) to 4.5 ng/mL (Feb 2025), with a velocity of 0.6 ng/mL/yr in the most recent interval.
get_previous_notes
Previous Notes: Dr. P. van Dijk documented the PSA increase from 3.0 ng/mL in November 2023 to 4.1 ng/mL by July 2024, noting the upward trend and the patient’s reluctance toward invasive testing, and an mpMRI was scheduled.
get_lab_results
Lab Results: PSA is 4.5 ng/mL (Feb 2025). Free PSA is 0.75 ng/mL (17%). eGFR is <60 mL/min/1.73m2.

NOT RETRIEVED
The family-history anamnesis was not retrieved, which could potentially provide context on genetic risk factors.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling:
- PSA trend shows a clear rising trajectory (velocity 0.6 ng/mL/yr).
- Previous notes confirm a documented upward trend and prior planning for imaging.
- The csPCa predicted probability is 0.5290899.

AGAINST Sampling:
- MRI report states "No PI-RADS 3+ lesion identified" and "PI-RADS NA".
- Guideline criterion suggests deferral when PI-RADS is 1-2, which aligns with the current NA/negative finding.

WHERE THIS LEANS
The evidence is divided: the clinical trend and prior history suggest a need for further investigation, but the current imaging data (PI-RADS NA, no 3+ lesion) aligns with the guideline criterion to defer biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the retrieved mpMRI report explicitly states 'No PI-RADS 3+ lesion identified' and 'PI-RADS NA', aligning with the EXPERT-PROTOCOL criterion for deferral when PI-RADS is 1-2. Although the PSA velocity was rising at 0.6 ng/mL/yr, the absence of a high-risk lesion on imaging overrides the statistical prior suggesting biopsy. The evidence converges on deferral based on the current imaging findings.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
